Cargando…

Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: A randomised clinical trial

BACKGROUND: To test the hypothesis that 0.01% atropine eyedrops are a safe and effective myopia‐control approach in Australian children. METHODS: Children (6–16 years; 49% Europeans, 18% East Asian, 22% South Asian, and 12% other/mixed ancestry) with documented myopia progression were enrolled into...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Samantha Sze‐Yee, Lingham, Gareth, Blaszkowska, Magdalena, Sanfilippo, Paul G., Koay, Adrian, Franchina, Maria, Chia, Audrey, Loughman, James, Flitcroft, Daniel Ian, Hammond, Christopher J., Azuara‐Blanco, Augusto, Crewe, Julie M., Clark, Antony, Mackey, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086806/
https://www.ncbi.nlm.nih.gov/pubmed/36054556
http://dx.doi.org/10.1111/ceo.14148
_version_ 1785022222920843264
author Lee, Samantha Sze‐Yee
Lingham, Gareth
Blaszkowska, Magdalena
Sanfilippo, Paul G.
Koay, Adrian
Franchina, Maria
Chia, Audrey
Loughman, James
Flitcroft, Daniel Ian
Hammond, Christopher J.
Azuara‐Blanco, Augusto
Crewe, Julie M.
Clark, Antony
Mackey, David A.
author_facet Lee, Samantha Sze‐Yee
Lingham, Gareth
Blaszkowska, Magdalena
Sanfilippo, Paul G.
Koay, Adrian
Franchina, Maria
Chia, Audrey
Loughman, James
Flitcroft, Daniel Ian
Hammond, Christopher J.
Azuara‐Blanco, Augusto
Crewe, Julie M.
Clark, Antony
Mackey, David A.
author_sort Lee, Samantha Sze‐Yee
collection PubMed
description BACKGROUND: To test the hypothesis that 0.01% atropine eyedrops are a safe and effective myopia‐control approach in Australian children. METHODS: Children (6–16 years; 49% Europeans, 18% East Asian, 22% South Asian, and 12% other/mixed ancestry) with documented myopia progression were enrolled into this single‐centre randomised, parallel, double‐masked, placebo‐controlled trial and randomised to receive 0.01% atropine (n = 104) or placebo (n = 49) eyedrops (2:1 ratio) instilled nightly over 24 months (mean index age = 12.2 ± 2.5 and 11.2 ± 2.8 years, respectively). Outcome measures were the changes in spherical equivalent (SE) and axial length (AL) from baseline. RESULTS: At 12 months, the mean SE and AL change from baseline were −0.31D (95% confidence interval [CI] = −0.39 to −0.22) and 0.16 mm (95%CI = 0.13–0.20) in the atropine group and −0.53D (95%CI = −0.66 to −0.40) and 0.25 mm (95%CI = 0.20–0.30) in the placebo group (group difference p ≤ 0.01). At 24 months, the mean SE and AL change from baseline was −0.64D (95%CI = −0.73 to −0.56) and 0.34 mm (95%CI = 0.30–0.37) in the atropine group, and −0.78D (95%CI = −0.91 to −0.65) and 0.38 mm (95%CI = 0.33–0.43) in the placebo group. Group difference at 24 months was not statistically significant (p = 0.10). At 24 months, the atropine group had reduced accommodative amplitude and pupillary light response compared to the placebo group. CONCLUSIONS: In Australian children, 0.01% atropine eyedrops were safe, well‐tolerated, and had a modest myopia‐control effect, although there was an apparent decrease in efficacy between 18 and 24 months, which is likely driven by a higher dropout rate in the placebo group.
format Online
Article
Text
id pubmed-10086806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-100868062023-04-12 Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: A randomised clinical trial Lee, Samantha Sze‐Yee Lingham, Gareth Blaszkowska, Magdalena Sanfilippo, Paul G. Koay, Adrian Franchina, Maria Chia, Audrey Loughman, James Flitcroft, Daniel Ian Hammond, Christopher J. Azuara‐Blanco, Augusto Crewe, Julie M. Clark, Antony Mackey, David A. Clin Exp Ophthalmol ORIGINAL ARTICLES BACKGROUND: To test the hypothesis that 0.01% atropine eyedrops are a safe and effective myopia‐control approach in Australian children. METHODS: Children (6–16 years; 49% Europeans, 18% East Asian, 22% South Asian, and 12% other/mixed ancestry) with documented myopia progression were enrolled into this single‐centre randomised, parallel, double‐masked, placebo‐controlled trial and randomised to receive 0.01% atropine (n = 104) or placebo (n = 49) eyedrops (2:1 ratio) instilled nightly over 24 months (mean index age = 12.2 ± 2.5 and 11.2 ± 2.8 years, respectively). Outcome measures were the changes in spherical equivalent (SE) and axial length (AL) from baseline. RESULTS: At 12 months, the mean SE and AL change from baseline were −0.31D (95% confidence interval [CI] = −0.39 to −0.22) and 0.16 mm (95%CI = 0.13–0.20) in the atropine group and −0.53D (95%CI = −0.66 to −0.40) and 0.25 mm (95%CI = 0.20–0.30) in the placebo group (group difference p ≤ 0.01). At 24 months, the mean SE and AL change from baseline was −0.64D (95%CI = −0.73 to −0.56) and 0.34 mm (95%CI = 0.30–0.37) in the atropine group, and −0.78D (95%CI = −0.91 to −0.65) and 0.38 mm (95%CI = 0.33–0.43) in the placebo group. Group difference at 24 months was not statistically significant (p = 0.10). At 24 months, the atropine group had reduced accommodative amplitude and pupillary light response compared to the placebo group. CONCLUSIONS: In Australian children, 0.01% atropine eyedrops were safe, well‐tolerated, and had a modest myopia‐control effect, although there was an apparent decrease in efficacy between 18 and 24 months, which is likely driven by a higher dropout rate in the placebo group. John Wiley & Sons Australia, Ltd 2022-09-09 2022-12 /pmc/articles/PMC10086806/ /pubmed/36054556 http://dx.doi.org/10.1111/ceo.14148 Text en © 2022 The Authors. Clinical & Experimental Ophthalmology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Ophthalmologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle ORIGINAL ARTICLES
Lee, Samantha Sze‐Yee
Lingham, Gareth
Blaszkowska, Magdalena
Sanfilippo, Paul G.
Koay, Adrian
Franchina, Maria
Chia, Audrey
Loughman, James
Flitcroft, Daniel Ian
Hammond, Christopher J.
Azuara‐Blanco, Augusto
Crewe, Julie M.
Clark, Antony
Mackey, David A.
Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: A randomised clinical trial
title Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: A randomised clinical trial
title_full Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: A randomised clinical trial
title_fullStr Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: A randomised clinical trial
title_full_unstemmed Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: A randomised clinical trial
title_short Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: A randomised clinical trial
title_sort low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of australian children: a randomised clinical trial
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086806/
https://www.ncbi.nlm.nih.gov/pubmed/36054556
http://dx.doi.org/10.1111/ceo.14148
work_keys_str_mv AT leesamanthaszeyee lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT linghamgareth lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT blaszkowskamagdalena lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT sanfilippopaulg lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT koayadrian lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT franchinamaria lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT chiaaudrey lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT loughmanjames lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT flitcroftdanielian lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT hammondchristopherj lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT azuarablancoaugusto lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT crewejuliem lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT clarkantony lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial
AT mackeydavida lowconcentrationatropineeyedropsformyopiacontrolinamultiracialcohortofaustralianchildrenarandomisedclinicaltrial